Anterogen.Co.,Ltd. (KOSDAQ:065660)

South Korea flag South Korea · Delayed Price · Currency is KRW
35,900
-50 (-0.14%)
At close: Feb 27, 2026
99.11%
Market Cap 359.22B
Revenue (ttm) 7.32B
Net Income (ttm) -1.91B
Shares Out 10.01M
EPS (ttm) -193.30
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17,255
Average Volume 22,335
Open 36,000
Previous Close 35,950
Day's Range 35,050 - 36,750
52-Week Range 16,510 - 51,000
Beta 0.33
RSI 37.89
Earnings Date n/a

About Anterogen.Co.,Ltd.

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn’s fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 065660
Full Company Profile

Financial Performance

In 2024, Anterogen.Co.,Ltd.'s revenue was 6.93 billion, an increase of 6.66% compared to the previous year's 6.50 billion. Losses were -2.29 billion, -19.29% less than in 2023.

Financial Statements

News

There is no news available yet.